| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.23 | 5e-07 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-06 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | 0.16 | 6e-05 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.21 | 0.0003 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0004 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0005 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0005 |
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0006 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0007 |